Actively Recruiting
Treatment of Refractory Skin Henoch-Schonlein Purpura in Children Ages 1 to 18 Using Leflunomide Combined with Steroids
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2023-07-10
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of leflunomide combined with steroid therapy to treat children with refractory skin Henoch-Schonlein Purpura HSP, a condition characterized by dense, large-area rashes that do not improve with standard treatments. This prospective, multicenter clinical trial aims to explore the safety and effectiveness of adding leflunomide to conventional therapy, with a one-year follow-up to monitor key health indicators. Children in this study will receive leflunomide after showing persistent or recurrent rashes despite treatment with antibiotics, antihistamines, calcium supplements, and glucocorticoids at a dose of 2 mgkg per day for 5 days. The study focuses on those whose rash recurs more than three times during hospitalization. Leflunomide is administered alongside the conventional treatment as part of a single-arm trial. Participants will be monitored over 12 months to track changes in rash recurrence frequency, kidney involvement, joint symptoms, T lymphocyte subpopulations, and inflammatory factors. Researchers will assess safety and treatment responses through clinical observations and laboratory measures during this period. The total participation time covers the treatment phase and one year of follow-up to evaluate lasting effects.
CONDITIONS
Brief Title
Leflunomide for Henoch-Schonlein Purpura
Research Team
H
Haiyan Wang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here